Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL242 in advanced solid tumors
NCT07197827Phase 2Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 2, open-label trial of YL242 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) and 3 more, sponsored by MediLink Therapeutics. Primary endpoints: Objective Response Rate at 36 months and Treatment-emergent Adverse Events at 36 months. Started Sep 2025; status: recruiting.
02
Drugs
YL242
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT07197827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197827.